In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
News|Podcasts|October 5, 2026
ACT Brief: AI Adoption Starting Points, Hierarchical Endpoints and Patient Priorities, and Early-Stage Program Termination
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In
part six and final segment of her interview , Claire Riches, VP of clinical solutions at Citeline, offers practical guidance for clinical operations teams beginning their AI journey. She makes the case that the tools are more accessible than many assume and that waiting to start is itself a competitive risk in a landscape where AI-informed trial design is becoming table stakes. - In a
new feature article , Samuel Salvaggio examined why hierarchical endpoints analyzed through pairwise comparisons more accurately reflect multifaceted treatment benefit than time-to-first-event composites. Transparent outcome prioritization, patient involvement in ranking endpoints, and clear reporting of net treatment benefit remain underutilized despite their importance to interpretation and regulatory credibility. Foghorn Therapeutics and Eli Lilly discontinued their early cancer treatment after Phase I data showed insufficient antitumor activity despite acceptable safety , even though the drug hit mechanistic targets in preclinical work. The termination reflects a broader industry shift toward cutting weak programs at the earliest stage rather than advancing them into costlier late-phase trials, with Phase I now accounting for 38% of all disclosed failures, up from 32% in 2020, while approval-stage failures have dropped below one percent.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today’s ACT Brief, we examine how AI is moving into continuous clinical operating models, how trust is built into oncology real-world evidence, and how the FDA approved a self-administered option for thyroid eye disease.
In today’s ACT Brief, we examine who decides what trials measure, how designing for human thinking improves site execution, and how the FDA extended an immunotherapy to a new bladder cancer population.
In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about why a well-written protocol doesn’t always translate into consistent execution, and how designing for the way people actually think and learn can reduce site burden and the need for costly unlearning.
In today’s ACT Brief, we examine what it will take to scale EHR-to-EDC connections for real-time trials, how the FDA is reimagining rare disease drug development, and why oncology real-world evidence still faces persistent data barriers.
In today's ACT Brief, we examine how representation gaps in trials are shaped by structural design decisions, how new partnerships automate data transfer from site systems to sponsor platforms, and how Roche is licensing a novel obesity target from a biotech pioneer.
Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
Trending on Applied Clinical Trials Online
1
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
2
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
3
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
4
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
5